Evidence map›Paper›PMID 38581576›Full record

ArticlePediatric surgery international2024

Comparison of two formulations of intravenous lipid emulsions in pediatric intestinal failure.

Mamta Naik, Alexandria Lawrence, Allison Davidson, John Chapman, Dalya Ferguson, Allison L Speer, Essam Imseis

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric surgery international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Mamta NaikDepartment of Pharmacy Services, Children's Memorial Hermann Hospital - Texas Medical Center, 6411 Fannin Street, Houston, TX, 77030, USA. Mamta.Naik@memorialhermann.org.
Alexandria LawrenceDepartment of Pediatrics, Monroe Carell Jr. Children's Hospital at Vanderbilt, Vanderbilt University Medical Center, Nashville, TN, USA.
Allison DavidsonDepartment of Pediatrics, Division of Neonatal-Perinatal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
John ChapmanShort Bowel Syndrome Therapy and Rehabilitation (STAR) Team, McGovern Medical School, Texas Medical Center, The University of Texas Health Science Center at Houston and Children's Memorial Hermann Hospital, Houston, TX, USA.
Dalya FergusonDepartment of Pediatric Surgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Allison L SpeerShort Bowel Syndrome Therapy and Rehabilitation (STAR) Team, McGovern Medical School, Texas Medical Center, The University of Texas Health Science Center at Houston and Children's Memorial Hermann Hospital, Houston, TX, USA.
Essam ImseisShort Bowel Syndrome Therapy and Rehabilitation (STAR) Team, McGovern Medical School, Texas Medical Center, The University of Texas Health Science Center at Houston and Children's Memorial Hermann Hospital, Houston, TX, USA.
The University of Texas Health Science Center at Houston · USMemorial Hermann · USTexas Medical Center · USVanderbilt University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe effect of different types of lipid emulsion may guide therapy of patients with intestinal failure (IF) to limit morbidity such as intestinal failure-associated liver disease (IFALD).

methodsA retrospective chart review of pediatric patients with IF who received soybean oil lipid emulsion (SL) or mixed oil lipid emulsion (ML) was performed. Data over 1 year were collected.

resultsForty-five patients received SL and 34 received ML. There were no differences in the incidence (82 versus 74%, P = 0.35) or resolution (86 versus 92%, P = 0.5) of IFALD between the cohorts. The median dose of ML was higher compared to SL (2 versus 1 g/kg/day, P < 0.001). If resolved, IFALD resolved rapidly in the ML cohort compared to the SL cohort (67 versus 37 days, P = 0.01). Weight gain was higher in the ML compared to the SL cohort at resolution of IFALD or 1 year from diagnosis of IF (P = 0.009).

conclusionThe administration of ML did not alter the incidence or resolution of IFALD compared to SL in pediatric IF. There was rapid resolution of IFALD and enhanced weight gain in the ML cohort compared to SL in pediatric IF.

Indexed as

Intestinal DiseasesIntestinal FailureLiver DiseasesLiver FailureChildFat Emulsions, IntravenousFish OilsHumansParenteral NutritionRetrospective StudiesSoybean OilWeight GainFat Emulsions, IntravenousFish OilsSoybean OilIntestinal failure-associated liver diseaseMixed oil lipid emulsionParenteral nutritionSoybean oil lipid emulsion

Identifiers

PMID38581576
OpenAlexW4394012838

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.